For research use only. Not for therapeutic Use.
Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in people in whom high doses of furosemide are ineffective. It is marketed by Hoffmann-La Roche. The main difference between the two substances is in bioavailability and pharmacodynamic potency. Furosemide is incompletely absorbed in the intestine (60%), and there are substantial inter- and intraindividual differences in bioavailability (range 10-90%). Bumetanide is almost completely absorbed (80%), and the absorption is not altered when it is taken with food. It is said to be a more predictable diuretic, meaning that the predictable absorption is reflected in a more predictable effect.
| Catalog Number | A000244 |
| CAS Number | 28395-03-1 |
| Synonyms | 28395-03-1; 3-(Butylamino)-4-phenoxy-5-sulfamoylbenzoic acid; Bumex; Burinex; Fordiuran |
| Molecular Formula | C17H20N2O5S |
| Purity | ≥95% |
| Target | NKCC |
| Solubility | >18.2mg/mL in DMSO |
| Storage | -20°C |
| InChI | 1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23) |
| InChIKey | MAEIEVLCKWDQJH-UHFFFAOYSA-N |
| SMILES | CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2 |
| Reference | 1: Vlaskamp C, Poil SS, Jansen F, Linkenkaer-Hansen K, Durston S, Oranje B, 2: Hu D, Yu ZL, Zhang Y, Han Y, Zhang W, Lu L, Shi J. Bumetanide treatment during 3: Fluegge K. Bumetanide Treatment for Psychiatric Disorders and the Modulation 4: Lemonnier E, Villeneuve N, Sonie S, Serret S, Rosier A, Roue M, Brosset P, 5: Lemonnier E, Villeneuve N, Sonie S, Serret S, Rosier A, Roue M, Brosset P, <br> <br> 8: Tang L, Fang X, Winesett SP, Cheng CY, Binder HJ, Rivkees SA, Cheng SX. 9: Rahmanzadeh R, Eftekhari S, Shahbazi A, Khodaei Ardakani MR, Rahmanzade R, <br> |
